Mary-louise J. Rogers

Bedford Park
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Reply to letter to editor "Clarifying exposure heterogeneity in a review of HERVs and neurodegenerative diseases".

Reply to letter to editor "Clarifying exposure heterogeneity in a review of HERVs and neurodegenerative diseases".

Journal: Brain, behavior, and immunity
Published: May 20, 2026

Evaluation of triumeq treatment on a TDP-43 mouse model of amyotrophic Lateral sclerosis.

Evaluation of triumeq treatment on a TDP-43 mouse model of amyotrophic Lateral sclerosis.

Journal: Scientific reports
Published: February 05, 2026

The differences in sex ratio between sporadic and familial amyotrophic lateral sclerosis: a systematic review.

The differences in sex ratio between sporadic and familial amyotrophic lateral sclerosis: a systematic review.

Journal: Journal of neurology
Published: December 07, 2025

The roles of human endogenous retrovirus in neurodegenerative diseases: A systematic review.

The roles of human endogenous retrovirus in neurodegenerative diseases: A systematic review.

Journal: Brain, behavior, and immunity
Published: July 23, 2025

Identification of a presymptomatic and early disease signature for Amyotrophic Lateral Sclerosis (ALS): protocol of the premodiALS study.

Identification of a presymptomatic and early disease signature for Amyotrophic Lateral Sclerosis (ALS): protocol of the premodiALS study.

Journal: medRxiv : the preprint server for health sciences
Published: June 10, 2025

Identification of a presymptomatic and early disease signature for amyotrophic lateral sclerosis (ALS): protocol of the premodiALS study.

Identification of a presymptomatic and early disease signature for amyotrophic lateral sclerosis (ALS): protocol of the premodiALS study.

Journal: Neurological research and practice
Published: May 14, 2025

Urinary P75: a promising biomarker for amyotrophic lateral sclerosis.

Urinary P75: a promising biomarker for amyotrophic lateral sclerosis.

Journal: BMJ neurology open
Published: March 04, 2025

Pathological forms of TDP-43 in amyotrophic lateral sclerosis (ALS) promote aberrant telomere elongation.

Pathological forms of TDP-43 in amyotrophic lateral sclerosis (ALS) promote aberrant telomere elongation.

Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: November 21, 2024

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.

Journal: medRxiv : the preprint server for health sciences
Published: August 26, 2024

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Neurology
Published: May 23, 2024

Sustainability-Driven Accelerated Shear-Mediated Immunoassay for Amyotrophic Lateral Sclerosis Detection.

Sustainability-Driven Accelerated Shear-Mediated Immunoassay for Amyotrophic Lateral Sclerosis Detection.

Journal: ChemSusChem
Published: May 10, 2024

Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.

Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.

Journal: EBioMedicine
Published: February 08, 2024
Showing 1-12 of 40

Last Updated: 09/26/2026